(Q34631422)

3 August 2017

1 reference

title

Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach (English)

1 reference

3 August 2017

1 reference

1 reference

1 reference

3

Arnaud Didierlaurent

1 reference

3 August 2017

Nathalie Garçon

1

1 reference

3 August 2017

Sandra Morel

2

1 reference

3 August 2017

Dominique Descamps

4

1 reference

3 August 2017

Martine Wettendorff

5

1 reference

3 August 2017

Marcelle Van Mechelen

6

1 reference

3 August 2017

1 August 2011

1 reference

3 August 2017

1 reference

3 August 2017

25

1 reference

3 August 2017

4

1 reference

3 August 2017

217-226

1 reference

https://scigraph.springernature.com/pub.10.2165/11591760-000000000-00000

3 August 2017

0 references

cites work

AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Vaccines: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Pathogen recognition and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

The danger model: a renewed sense of self

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

(How) do aluminium adjuvants work?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Vaccine adjuvants revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

The perfect mix: recent progress in adjuvant research

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Immunogenicity and protectivity of a new liposomal hepatitis A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Virosomal adjuvanted antigen delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Vaccines against intracellular infections requiring cellular immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

T cell immunity in neonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Immunosenescence: role and measurement in influenza vaccine response among the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

How bacteria and their products provide clues to vaccine and adjuvant development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Translating innate immunity into immunological memory: implications for vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Immunological foundations to the quest for new vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

The carcinogenicity of human papillomavirus types reflects viral evolution.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Classification of papillomaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Epidemiologic classification of human papillomavirus types associated with cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Chapter 2: The burden of HPV-related cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

The papillomavirus life cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Human papillomavirus immortalization and transformation functions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Natural history of human papillomavirus type 16 virus-like particle antibodies in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Regulation and function of NF-kappaB transcription factors in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Differential regulation of TLR4 expression in human B cells and monocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Toll-like receptor stimulation as a third signal required for activation of human naive B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

Autoimmune diseases after adolescent or adult immunization: what should we expect?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591760-000000000-00000

10.2165/11591760-000000000-00000

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference